EX-99.1
3
dp64764_ex9901.htm
EXHIBIT 99.1
Exhibit 99.1
NEWS RELEASE
CHARLES RIVER LABORATORIES COMPLETES
THE ACQUISITION OF WIL RESEARCH
WILMINGTON, MA, April 4, 2016
- Charles River Laboratories
International, Inc. (NYSE: CRL) announced today that it has completed the previously announced acquisition of WIL Research for
approximately $585 million in cash, subject to certain customary adjustments.
WIL Research is a premier provider of safety assessment and
contract development and manufacturing (CDMO) services to biopharmaceutical and agricultural and industrial chemical companies
worldwide. Acquiring WIL Research enhances Charles River's position as a leading global early-stage contract research organization
(CRO) by strengthening its ability to partner with global clients across the drug discovery and development continuum.
James C. Foster, Chairman, President, and Chief Executive Officer
of Charles River Laboratories, commented, "We are pleased to welcome the exceptional team at WIL Research to the Charles
River family. WIL reinforces our scientific leadership, adding a wealth of talent with deep expertise in specialty areas. Our combined
capabilities and larger infrastructure will enhance our ability to support our clients' complex drug research and development
needs, enabling them to make critical go/no-go decisions faster and with greater certainty. The acquisition of WIL Research is
a key element of our continued ability to support our clients' early-stage drug research efforts, to achieve our long-term
growth goals, and to enhance shareholder value".
Caution Concerning Forward-Looking Statements
This news release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of
words such as "anticipate", "believe", "expect", "will", "may", "estimate,"
"plan", "outlook", and "project" and other similar expressions that predict or indicate future
events or trends or that are not statements of historical matters. Forward-looking statements include statements in this news release
regarding the acquisition of WIL Research and Charles River's expectations with respect to the impact of WIL Research on
the Company, its service offerings, client perception, revenue, revenue growth rates, and earnings; Charles River's projected
future performance including revenue and earnings per share; Charles River's expected operational synergies; as well as Charles
River's future growth in the area of safety assessment and contract development and manufacturing. Forward-looking statements
are based on Charles River's current expectations and beliefs, and involve a number of risks and
1
uncertainties that are difficult to predict and that could cause
actual results to differ materially from those stated or implied by the forward-looking statements. Those risks and uncertainties
include, but are not limited to, the ability to successfully integrate the acquisition of WIL Research. A further description of
these risks, uncertainties, and other matters can be found in the Risk Factors detailed in Charles River's Annual Report on Form
10-K as filed on February 12, 2016, as well as other filings we make with the Securities and Exchange Commission. Because forward-looking
statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected
by Charles River, and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this
news release except as required by law.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to
improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them.
To learn more about our unique portfolio and breadth of services, visit www.criver.com.
About Charles River
Charles River provides essential products
and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the
globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with
exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for
the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
# # #
Investor Contact:
Media Contact:
Susan E. Hardy
Amy Cianciaruso
Corporate Vice President, Investor Relations
Corporate Vice President, Public Relations
781.222.6190
781.222.6168
susan.hardy@crl.com
amy.cianciaruso@crl.com
2

EX - 99 . 1 3 dp64764 _ ex9901 . htm EXHIBIT 99 . 1 Exhibit 99 . 1 NEWS RELEASE CHARLES RIVER LABORATORIES COMPLETES THE ACQUISITION OF WIL RESEARCH WILMINGTON , MA , April 4 , 2016 - Charles River Laboratories International , Inc . ( NYSE : CRL ) announced today that it has completed the previously announced acquisition of WIL Research for approximately $ 585 million in cash , subject to certain customary adjustments . WIL Research is a premier provider of safety assessment and contract development and manufacturing ( CDMO ) services to biopharmaceutical and agricultural and industrial chemical companies worldwide . Acquiring WIL Research enhances Charles River 's position as a leading global early - stage contract research organization ( CRO ) by strengthening its ability to partner with global clients across the drug discovery and development continuum . James C. Foster , Chairman , President , and Chief Executive Officer of Charles River Laboratories , commented , " We are pleased to welcome the exceptional team at WIL Research to the Charles River family . WIL reinforces our scientific leadership , adding a wealth of talent with deep expertise in specialty areas . Our combined capabilities and larger infrastructure will enhance our ability to support our clients ' complex drug research and development needs , enabling them to make critical go / no - go decisions faster and with greater certainty . The acquisition of WIL Research is a key element of our continued ability to support our clients ' early - stage drug research efforts , to achieve our long - term growth goals , and to enhance shareholder value " . Caution Concerning Forward - Looking Statements This news release includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements may be identified by the use of words such as " anticipate " , " believe " , " expect " , " will " , " may " , " estimate , " " plan " , " outlook " , and " project " and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters . Forward - looking statements include statements in this news release regarding the acquisition of WIL Research and Charles River 's expectations with respect to the impact of WIL Research on the Company , its service offerings , client perception , revenue , revenue growth rates , and earnings ; Charles River ' s projected future performance including revenue and earnings per share ; Charles River ' s expected operational synergies ; as well as Charles River 's future growth in the area of safety assessment and contract development and manufacturing . Forward - looking statements are based on Charles River 's current expectations and beliefs , and involve a number of risks and 1 uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward - looking statements . Those risks and uncertainties include , but are not limited to , the ability to successfully integrate the acquisition of WIL Research . A further description of these risks , uncertainties , and other matters can be found in the Risk Factors detailed in Charles River 's Annual Report on Form 10 - K as filed on February 12 , 2016 , as well as other filings we make with the Securities and Exchange Commission . Because forward - looking statements involve risks and uncertainties , actual results and events may differ materially from results and events currently expected by Charles River , and Charles River assumes no obligation and expressly disclaims any duty to update information contained in this news release except as required by law . About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies , government agencies and leading academic institutions around the globe accelerate their research and drug development efforts . Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery , early - stage development and safe manufacture of new therapies for the patients who need them . To learn more about our unique portfolio and breadth of services , visit www.criver.com . About Charles River Charles River provides essential products and services to help pharmaceutical and biotechnology companies , government agencies and leading academic institutions around the globe accelerate their research and drug development efforts . Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery , early - stage development and safe manufacture of new therapies for the patients who need them . To learn more about our unique portfolio and breadth of services , visit www.criver.com . # # # Investor Contact : Media Contact : Susan E. Hardy Amy Cianciaruso Corporate Vice President , Investor Relations Corporate Vice President , Public Relations 781 . 222 . 6190 781 . 222 . 6168 susan.hardy@crl.com amy.cianciaruso@crl.com 2